Zucker Michal, Zivelin Ariella, Teitel Jerome, Seligsohn Uri
Amalia Biron Research Institute of Thrombosis and Hemostasis, Chaim Sheba Medical Center, Tel-Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Blood. 2008 Feb 1;111(3):1306-8. doi: 10.1182/blood-2007-08-108449. Epub 2007 Nov 20.
In this paper, we report an inhibitor antibody to factor XI (FXI) in a woman with severe inherited FXI deficiency, induced by FXI present in an Rh immune globulin preparation. The patient is homozygous for the Glu117Stop mutation, associated with a FXI level of less than 1 U/dL. Unlike all previously described patients with severe FXI deficiency and an inhibitor, the patient had never been exposed to blood products. Following 3 injections of Rh immune globulin during pregnancy, she developed an inhibitor to FXI (8 Bethesda units) that was shown to bind specifically to FXI and inhibit factor IX cleavage by purified FXIa. The administered Rh immune globulin and 2 other similar products were shown to contain FXI. Clinicians should be aware of the potential for immunization of severely FXI-deficient patients by FXI present in Rh immune globulin preparations.
在本文中,我们报告了一名患有严重遗传性因子 XI(FXI)缺乏症的女性体内产生了一种针对 FXI 的抑制性抗体,该抗体由 Rh 免疫球蛋白制剂中存在的 FXI 诱导产生。该患者为 Glu117Stop 突变的纯合子,其 FXI 水平低于 1 U/dL。与所有先前描述的患有严重 FXI 缺乏症且伴有抑制剂的患者不同,该患者从未接触过血液制品。在怀孕期间注射 3 次 Rh 免疫球蛋白后,她产生了一种针对 FXI 的抑制剂(8 贝塞斯达单位),该抑制剂被证明能特异性结合 FXI 并抑制纯化的 FXIa 对因子 IX 的裂解。所使用的 Rh 免疫球蛋白及其他 2 种类似产品被证明含有 FXI。临床医生应意识到 Rh 免疫球蛋白制剂中存在的 FXI 可能会使严重 FXI 缺乏的患者发生免疫反应。